- Home
- CISS vs ICU Comparison
CISS vs ICU Comparison
Compare CISS & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- ICU
- Stock Information
- Founded
- CISS 2022
- ICU 2018
- Country
- CISS Greece
- ICU United States
- Employees
- CISS N/A
- ICU N/A
- Industry
- CISS Marine Transportation
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- ICU Health Care
- Exchange
- CISS Nasdaq
- ICU Nasdaq
- Market Cap
- CISS 11.9M
- ICU 10.3M
- IPO Year
- CISS N/A
- ICU N/A
- Fundamental
- Price
- CISS $1.09
- ICU $2.12
- Analyst Decision
- CISS
- ICU
- Analyst Count
- CISS 0
- ICU 0
- Target Price
- CISS N/A
- ICU N/A
- AVG Volume (30 Days)
- CISS 110.7K
- ICU 24.8K
- Earning Date
- CISS 11-19-2024
- ICU 11-13-2024
- Dividend Yield
- CISS N/A
- ICU N/A
- EPS Growth
- CISS N/A
- ICU N/A
- EPS
- CISS N/A
- ICU N/A
- Revenue
- CISS $47,503,090.00
- ICU N/A
- Revenue This Year
- CISS N/A
- ICU N/A
- Revenue Next Year
- CISS N/A
- ICU $344.44
- P/E Ratio
- CISS N/A
- ICU N/A
- Revenue Growth
- CISS 264.29
- ICU N/A
- 52 Week Low
- CISS $1.08
- ICU $1.88
- 52 Week High
- CISS $68.50
- ICU $42.93
- Technical
- Relative Strength Index (RSI)
- CISS 38.87
- ICU 21.22
- Support Level
- CISS $1.13
- ICU $1.88
- Resistance Level
- CISS $1.17
- ICU $2.81
- Average True Range (ATR)
- CISS 0.05
- ICU 0.29
- MACD
- CISS -0.01
- ICU -0.05
- Stochastic Oscillator
- CISS 6.67
- ICU 10.92
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.